Liraglutide, a once-daily human GLP-1 analogue, reduces the prevalence of prediabetes in obese subjects over 20 weeks: a randomized placebo-controlled trial

被引：0

作者：

Finer, N. ^{[1
]}

Al Hakim, M. ^{[2
]}

Astrup, A. ^{[3
]}

Harper, A. ^{[4
]}

Lean, M. ^{[5
]}

Niskanen, L. ^{[6
]}

Rasmussen, M. F. ^{[4
]}

Rissanen, A. ^{[7
]}

Rossner, S. ^{[8
]}

Van Gaal, L. ^{[9
]}

机构：

[1] UCL, Dept Med, London WC1E 6BT, England

[2] EB FlevoRes, Almere, Netherlands

[3] Univ Copenhagen, Frederiksberg, Denmark

[4] Novo Nordisk AS, DK-2880 Bagsvaerd, Denmark

[5] Univ Glasgow, Glasgow G12 8QQ, Lanark, Scotland

[6] Kuopio Univ Hosp, Kuopio, Finland

[7] Univ Helsinki, Cent Hosp, FIN-00014 Helsinki, Finland

[8] Karolinska Univ Hosp, Huddinge, Sweden

[9] Univ Antwerp Hosp, Antwerp, Belgium

来源：

DIABETOLOGIA | 2009年 / 52卷

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：S11 / S12

页数：2

共 50 条

[1] Liraglutide, a Once-Daily Human GLP-1 Analog, Reverses Indices of Prediabetes in Obese Subjects: A Randomized Placebo-Controlled 20-Week Trial
Finer, Nick
Al Hakim, Mazin
Astrup, Arne
Harper, Angela
Lean, Mike
Niskanen, Leo
Rasmussen, Mads F.
Rissanen, Aila
Roessner, Stephan
Van Gaal, Luc
DIABETES, 2009, 58 : A443 - A444
[2] Treatment with Liraglutide, a Once-Daily Human GLP-1 Analog, for 52 Weeks Reduces Weight and Waist Circumference: A Randomized Placebo-Controlled Trial
Astrup, Arne
Al Hakim, Mazin
Savolainen, Markku J.
Van Gaal, Luc
Finer, Nick
Harper, Angela
Lean, Michael E. J.
Niskanen, Leo
Frederik, Mads
Rissanen, Aila
Rossner, Stephan
OBESITY, 2009, 17 : S51 - S51
[3] The Once-Daily Human GLP-1 Analog Liraglutide Reduces the Prevalence of Prediabetes and Improves Systolic Blood Pressure in Obese Non-Diabetic Subjects: A 52-Week, Randomized Placebo-Controlled Trial
Finer, Nick
Al Hakim, Mazin
Van Gaal, Luc
Astrup, Arne
Harper, Angela
Lean, Michael E. J.
Niskanen, Leo
Rasmussen, Mads Frederik
Rissanen, Aila
Rossner, Stephan
Savolainen, Markku J.
OBESITY, 2009, 17 : S108 - S108
[4] Liraglutide, a Once-Daily Human GLP-1 Analogue, Reduces Body Weight and Improves Obesity-Related Risk Factors in Obese Non-Diabetic Subjects: a Randomized Placebo-Controlled Trial
Astrup, Arne
Van Gaal, Luc
Rissanen, Aila
Niskanen, Leo
Al Hakim, Mazin
Madsen, Jesper
Rasmussen, Mads Frederik
Rossner, Stephan
OBESITY, 2008, 16 : S64 - S64
[5] The effect of the once-daily human GLP-1 analogue liraglutide on the pharmacokinetics of paracetamol
Kapitza, Christoph
Flint, Anne
Hindsberger, Charlotte
Zdravkovic, Milan
DIABETES, 2008, 57 : A593 - A593
[6] Molecular, pharmacological and clinical aspects of liraglutide, a once-daily human GLP-1 analogue
Russell-Jones, David
MOLECULAR AND CELLULAR ENDOCRINOLOGY, 2009, 297 (1-2) : 137 - 140
[7] Safety, tolerability, pharmacokineties and pharmacodynamics of the once-daily GLP-1 analogue liraglutide in healthy Japanese subjects
Irie, Shin
Matsumura, Yoriko
Zdravkovic, Milan
Jacobsen, Lisbeth V.
Kageyama, Shigeru
DIABETES, 2007, 56 : A540 - A540
[8] The once-daily human GLP-1 analogue liraglutide decreases postprandial hunger and energy intake
Flint, Anne
Kapitza, Christoph
Hinds-Berger, Charlotte
Zdravkovic, Milan
DIABETES, 2008, 57 : A165 - A165
[9] Mechanism of Protraction for Liraglutide, the Once-Daily Human GLP-1 Analog
Knudsen, Lotte B.
Nielsen, Per F.
Steensgaard, Dorte B.
Bloch, Paw
Lau, Jesper
Agersoe, Henrik
DIABETES, 2009, 58 : A532 - A532
[10] Liraglutide: a once-daily GLP-1 analogue for the treatment of Type 2 diabetes mellitus
Vilsboll, Tina
EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2007, 16 (02) : 231 - 237

← 1 2 3 4 5 →